The main objective of this study is to compare the adjusted odds of microvascular complications (defined as CKD stage ≥3, albuminuria, and diabetic retinopathy) versus macrovascular complications (defined as myocardial infarction, stroke, and coronary artery disease) among U.S. adults reporting GLP-1 receptor agonist use. Here, GLP1R is linked to chronic kidney disease.